

Biodol Therapeutics gathers €7 million to progress its oral, next-generation pain therapy into the clinic

Montarnaud, France, 21 May 2024 – Biodol Therapeutics, a French biotech company developing next-generation pain treatments announces its selection for funding by BPI France via the i-DEMO call for projects to finance its first-in-human clinical trials.

With the parallel support of the venture capital fund V-Bio Ventures, Biodol Therapeutics will lead a consortium also composed of 2 academic partners (Institute for Neurosciences of Montpellier and Laboratory for Therapeutic Innovation in Strasbourg), which will be eligible to receive a total of €7 million, either in equity and in non-dilutive, to develop its innovative program of small-molecule extracellular negative allosteric modulators (NAMs) of the FLT3 receptor.

The funding package will namely support the first-in-human clinical studies with the most advanced compound, BDT272, which has gathered an excellent and complete GLP safety/toxicology data package alongside with exceptional activity in a wide range of preclinical pain models.

The key role of the FLT3 receptor in pain mechanisms and the potential benefit of its specific extracellular inhibition have now been highlighted in several international scientific publications. FLT3 negative allosteric modulation is emerging as a promising drug development innovation in an indication with high medical needs.

Biodol Therapeutics is a French academic spin-off focused on innovative pain medication, backed by a portfolio of patents held in co-ownership with several French research institutes (Universities of Montpellier and Strasbourg, INSERM and CNRS).

Its program, approved by the 2 French competitiveness clusters Eurobiomed and Biovalley France, is perfectly aligned with the priorities of the France 2030 plan and the French government to develop innovative companies with high value products in growth markets to strengthen France's competitiveness and industrial capabilities.

The primary objective of the company is now to bring the BDT272 clinical candidate to the clinic by the end of 2024.

About Biodol Therapeutics

Biodol Therapeutics (www.biodol.eu), founded in 2015, develops first-in-class compounds for the treatment of chronic pain (CP). Biodol Therapeutics has identified the Receptor Tyrosine Kinase (RTK) FLT3 as a key player for triggering and maintaining the chronic neuropathic pain (NP) state. The company is focused on the development of allosteric inhibitors of the FLT3 receptor for the treatment of chronic pain. Biodol Therapeutics already owns the exclusive rights on a portfolio of 4 patents. The company has been supported by BPI France, Satt AxLR, Inserm Transfert, Region Occitanie, the French National Research Agency, SEMIA Incubator and Montpellier Business and Innovation Centre.

About V-Bio Ventures

V-Bio Ventures (www.v-bio.ventures) is an independent venture capital firm specialized in building and financing young, innovative life science companies. V-Bio Ventures was established in 2015 and works closely with Belgium-based VIB, one of the world's premier life science institutes. The fund invests throughout Europe in start-up and early-stage companies with high growth potential focusing on technologies that provide transformational improvements in the biopharmaceutical, pharmaceutical, diagnostics and agricultural sectors.

For more information, please contact:

Biodol Therapeutics

contact@biodol.eu